Valuation: Endonovo Therapeutics, Inc.

Market Cap 2.77M 2.42M 2.28M 2.07M 3.88M 266M 3.9M 27.35M 10.55M 135M 10.42M 10.19M 435M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.66M 8.17M 7.42M 13.91M 952M 13.96M 97.9M 37.78M 484M 37.29M 36.46M 1.56B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.02
5 years 0
Extreme 1.0E-6
0.04
10 years 0
Extreme 1.0E-6
170
Manager TitleAgeSince
Chief Executive Officer 61 2012-02-29
Investor Relations Contact - 2014-04-30
Corporate Officer/Principal 77 2022-11-29
Director TitleAgeSince
Chairman 61 2012-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/20 Buy

Chief Executive Officer

400 0.0045%
2/21/20 Buy

Chief Executive Officer

100 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-99.05% 1.81K
-0.31%+5.79%+48.93%+97.53% 70.89B
+0.39%+2.06%+40.91%+78.49% 62.32B
-3.21%-7.27%-17.73%+351.98% 27.07B
+0.50%+7.13%+29.43%+15.48% 26.2B
-2.64%-0.69%-0.26%-11.90% 24.78B
+0.71%+8.03%+27.22%-13.18% 20.59B
-1.26%-7.81%+169.33%+302.38% 15.52B
-0.22%+3.99%+44.28%+173.35% 14.49B
+0.73%+1.71%-7.18%+886.19% 14.14B
Average -0.53%+1.59%+33.49%+178.13% 27.6B
Weighted average by Cap. -0.49%+1.49%+36.35%+148.21%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 7.01 0.1 0.72 0.28 3.57 0.27 0.27 11.48 0.14 0.12 0.11 0.1 0.19 12.99 0.19 1.33 0.52 6.6 0.51 0.5 21.25
Net income -3.1M -2.71M -2.56M -2.32M -4.35M -298M -4.37M -30.62M -11.82M -151M -11.66M -11.4M -487M -18.47M -16.11M -15.21M -13.81M -25.88M -1.77B -25.99M -182M -70.32M -901M -69.4M -67.86M -2.9B
Net Debt 7.1M 6.19M 5.84M 5.3M 9.94M 681M 9.98M 69.98M 27M 346M 26.65M 26.06M 1.11B 7.15M 6.24M 5.89M 5.35M 10.02M 686M 10.06M 70.55M 27.22M 349M 26.87M 26.27M 1.12B
Logo Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
1
Date Price Change Volume
26-09-17 US$0.000001 -99.00% 5,000
26-09-16 US$0.000100 -.--% 40,000
26-09-14 US$0.000100 -.--% 270,000
26-09-10 US$0.000100 -.--% 1,000,000
  1. Stock Market
  2. Stocks
  3. ENDV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!